Insulin glargine (Toujeo)
Peptide
Evidence outlook
Approved: Type 2 Diabetes, Type 1 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Diabetes mellitus in adults and children from 6 years needing insulin (Toujeo 300 units/ml, previously Optisulin)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EDITION I NCT01499082 · Type 2 Diabetes The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result. Registry: NCT01499082 | 3 | Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6) 2013-01 | Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) | Partial signal | link ↗ |
View 1 more trial
EDITION II NCT01499095 · Type 2 Diabetes Registry: NCT01499095 | 3 | Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6) 2013-04 | Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.57 percentage of hemoglobin (Standard Error 0.094) | Lantus -0.56 percentage of hemoglobin (Standard Error 0.093) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 4 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
Other Insulin receptor (basal) drugs
insulin degludec, insulin detemir, Insulin Efsitora Alfa, insulin glargine, Insulin glargine (Basaglar) and 7 more. Compare all 13 Insulin receptor (basal) drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Insulin Glargine (Toujeo): this drug | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis). | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Human | Approved | — | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cadisegliatin | Phase 3 | Small molecule | Glucokinase | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.